Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Nations Financial Group Inc. IA ADV

Nations Financial Group Inc. IA ADV lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 37.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,524 shares of the company’s stock after buying an additional 3,982 shares during the period. Nations Financial Group Inc. IA ADV’s holdings in Amphastar Pharmaceuticals were worth $898,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. McGlone Suttner Wealth Management Inc. purchased a new position in Amphastar Pharmaceuticals in the 4th quarter worth approximately $28,000. Principal Securities Inc. acquired a new position in Amphastar Pharmaceuticals during the fourth quarter worth $34,000. Quadrant Capital Group LLC grew its holdings in Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after buying an additional 223 shares in the last quarter. Covestor Ltd increased its stake in shares of Amphastar Pharmaceuticals by 859.0% in the 3rd quarter. Covestor Ltd now owns 1,966 shares of the company’s stock worth $90,000 after acquiring an additional 1,761 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Amphastar Pharmaceuticals by 115.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock worth $150,000 after acquiring an additional 1,300 shares during the period. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at $1,006,160.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 14,000 shares of company stock worth $655,145. 27.10% of the stock is currently owned by company insiders.

Amphastar Pharmaceuticals Trading Down 0.2 %

Shares of AMPH traded down $0.09 during trading on Friday, reaching $43.26. 226,682 shares of the company traded hands, compared to its average volume of 360,819. The stock has a 50-day simple moving average of $42.10 and a 200-day simple moving average of $50.46. The stock has a market cap of $2.12 billion, a PE ratio of 14.97, a price-to-earnings-growth ratio of 0.89 and a beta of 0.85. Amphastar Pharmaceuticals, Inc. has a twelve month low of $38.43 and a twelve month high of $67.66. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. The company had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. On average, analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.6 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. started coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 price objective for the company. StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $66.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.